New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Lisata Therapeutics, Inc.

Contributing Author

Recent Articles by Lisata Therapeutics, Inc.

Jan-27	Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide LSTA GlobeNewswire
Jan-21	Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer LSTA GlobeNewswire
Nov-06	Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update LSTA GlobeNewswire
Nov-06	Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year' LSTA GlobeNewswire
Nov-04	Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent LSTA GlobeNewswire
Oct-30	Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 LSTA GlobeNewswire
Oct-08	Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement LSTA GlobeNewswire
Sep-29	Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial LSTA GlobeNewswire
Sep-02	Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference LSTA GlobeNewswire
Aug-07	Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update LSTA GlobeNewswire
Jul-31	Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025 LSTA GlobeNewswire
Jul-17	Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update LSTA GlobeNewswire
Jul-15	Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide LSTA GlobeNewswire
Jun-26	Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata's Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer LSTA GlobeNewswire
Jun-17	Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development LSTA GlobeNewswire
Jun-11	Lisata Therapeutics to Present at the 2025 BIO International Convention LSTA GlobeNewswire
May-08	Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update LSTA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.